checkdown-arrowsearchshare

This site is intended for healthcare professionals outside the U.S.

The OTEZLA® International Website


close x

You are now leaving Otezla.net!


OTEZLA delivers rapid and sustained efficacy1

OTEZLA sustains improvement in skin severity1

 

SUSTAINED PASI RESPONSE UP TO 32 WEEKS1,a

otezla showing pasi improvement at 32 weeks
a

ESTEEM® 1 study; full analysis set, data as observed.

ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; PASI, Psoriasis Area and Severity Index.

Reference: 1. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015. 


Select an e-mail client to share

close x